Advertisement

Public Health Implications of Emerging Vaccine Technologies

  • Dale N. Lawrence
  • Karen L. Goldenthal
  • John W. Boslego
  • Donna K. F. Chandler
  • John R. La Montagne
Part of the Pharmaceutical Biotechnology book series (PBIO, volume 6)

Abstract

This book provides insight into recent innovations or improved applications of existing technologies in the design of vaccines for the prevention of several specific diseases. It makes a broader contribution to the understanding of the vast array of technologies that support modern vaccinology. The objectives of this chapter are: (1) to provide an overview of how advances in vaccine-related technologies have fostered the development of vaccines with highly desirable characteristics for current and future public health vaccination programs; (2) to explore how the development and availability of such vaccines will shape public health concepts, policies, and practices; and (3) to explore how institutional and procedural changes may alter vaccine research and development, manufacture, and delivery to populations in need of immunization.

Keywords

Pertussis Vaccine Public Health Implication Cold Chain Rift Valley Fever Oral Poliovirus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aguado, M. T., 1993, Future approaches to vaccine development: Single-dose vaccines using controlledrelease delivery systems, Vaccine 10:596–597.CrossRefGoogle Scholar
  2. Aitkin, R. J., Paterson, M., and Koothan, P. T., 1993, Contraceptive vaccines, Br. Med. Bull. 49:88–99.Google Scholar
  3. Bancroft, W. H., and Lemon, S. M., 1984, Hepatitis A from the military perspective, in: Hepatitis A (R.J. Garety, ed.), Academic Press, New York, pp. 81–100.Google Scholar
  4. Black, S., and Shinefield, H., 1995, Comprehensive evaluation of vaccine safety: Assessment of local and systemic side effects as well as emergency and hospitalization utilization. Proceedings of the combined vaccines and simultaneous administration: Current issues and perspectives workshop, Ann. N. Y. Acad. Sci. (in press).Google Scholar
  5. Brown, K. R., and Douglas, R. G., Jr., 1994, New challenges in quality control and licensure: Regulation, Int. J. Tech. Assess. Health Care 10:55–64.CrossRefGoogle Scholar
  6. Center for Biologics Evaluation and Research/FDA, 1995, Combined vaccines and simultaneous administration: Current issues and perspectives (Workshop sponsored by CBER/FDA, NVPO, NIAID/NIH, CDC, WHO, and held in Bethesda, MD, July 28–30,1993), Proceedings to be published in Ann. N. Y. Acad. Sci. Centers for Disease Control, 1982, Measles Surveillance Report No. 11, 1977–1981; Issued September, 1982.Google Scholar
  7. Centers for Disease Control, 1986, Hepatitis B associated with jet gun injection — California, Morbid. Mortal. Weekly Rep. 35:373–376.Google Scholar
  8. Centers for Disease Control and Prevention, 1993, Hantavirus infection — Southwestern United States: Interim recommendations for risk reduction, Morbid. Mortal. Weekly Rep. 42(Suppl. RR-11): 1–13.Google Scholar
  9. Centers for Disease Control and Prevention, 1994a, General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP), Morbid. Mortal. Weekly Rep. 43(Suppl. RR-1):1–38.Google Scholar
  10. Centers for Disease Control and Prevention, 1994b, Progress toward elimination of Haemophilus influenzae type b disease among infants and children — United States, 1987–1993, Morbid. Mortal. Weekly Rep. 43(No. 8): 144–148.Google Scholar
  11. Cheng, L., Ziegelhoffer, P. R., and Yang, N.-S., 1993, In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment, Proc. Natl. Acad. Sci. USA 90:4455–4459.PubMedCrossRefGoogle Scholar
  12. Clemens, J., Brenner, R., and Rao, M., 1995, Interactions between PRP-T vaccine against Haemophilus influenzae type b and conventional infant vaccines: Lessons for further studies of simultaneous immunization and combined vaccines. Proceedings of the combined vaccines and simultaneous administration: Current issues and perspectives workshop, Ann. N.Y. Acad. Sci. (in press).Google Scholar
  13. Coates, J. B., Hoff, E. C., and Hoff, P. M., (eds.), 1963, Preventive Medicine in World War II. Vol. VI. Communicable Diseases: Malaria, Office of the Surgeon General, Department of the Army, Washington, DC.Google Scholar
  14. Cohen, S., Alonso, J. J., and Langer, R., 1994, Novel approaches to controlled-release antigen delivery, Int. J. Tech. Assess. Health Care 10:121–130.CrossRefGoogle Scholar
  15. de Quadros, C. A., Carrasco, P., and Olive, J.-M., 1994, The desired field-performance characteristics of new improved vaccines for the developing world, Int. J. Tech. Assess. Health Care 10:65–70.CrossRefGoogle Scholar
  16. Edelman, R., and Tacket, C. O., 1990, Adjuvants, Int. Rev. Immunol. 7:51–66.PubMedCrossRefGoogle Scholar
  17. Ellis, R. W., and Douglas, R. G., Jr., 1994, New vaccine technologies, J. Am. Med. Assoc. 271:929–931.CrossRefGoogle Scholar
  18. Fynan, E. F., Webster, R. G., Fuller, D. H., Haynes J. R., Santoro, J. C., and Robinson, H. L., 1993, DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations, Proc. Natl. Acad. Sci. USA. 90:11478–11482.PubMedCrossRefGoogle Scholar
  19. Goldenthal, K. L., and McVittie, L. D., 1993, The clinical testing of preventive vaccines, in: Biologies Development: A Regulatory Overview (M. Mathieu, ed.), Parexel International Corp., Waltham, MA, pp. 119–130.Google Scholar
  20. Goldenthal, K. L., Cavagnaro, J. A., Alving, C. R., and Vogel, F. R., 1993, Safety evaluation of vaccine adjuvants: National cooperative vaccine development meeting working group, AIDS Res. Hum. Retroviruses 9:S47–S51.Google Scholar
  21. Henderson, D.A., and Fenner, F., 1994, Smallpox and vaccinia, in: Vaccines, 2nd ed. (S.A. Plotkin and E.A. Mortimer, Jr., eds.), Saunders, Philadelphia, pp. 13–40.Google Scholar
  22. Hoke, C. H., Jr., Binn, L. N., Egan, J. E., DeFraites, R. F., MacArthy, P. O., Innis, B. L., Eckels, K. H., Dubois, D., D’Hondt, E., Sjogren, M. H., Rice, R., Sadoff, J. C., and Bancroft, W. H., 1992, Hepatitis A in the US Army: Epidemiology and vaccine development, Vaccine 10(Suppl. 1):S75–S79.PubMedCrossRefGoogle Scholar
  23. Homma, A., and Knouss, R. F., 1994, The transfer of vaccine technology to developing countries. The Latin American experience, Int. J. Tech. Assess. Health Care 10:47–54.CrossRefGoogle Scholar
  24. Hopkins, D. R., 1983, Princes and Peasants: Smallpox in History, University of Chicago Press, Chicago.Google Scholar
  25. The International Bank for Reconstruction and Development/World Bank, 1993, World Development Report 1993. Investing in Health, Oxford University Press, London.Google Scholar
  26. Johansson, B. E., Grajower, B., and Kilbourne, E. D., 1993, Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice, Vaccine 11:1037–1039.PubMedCrossRefGoogle Scholar
  27. Jones, W. R., Bradley, J., Judd, S. J., Denholm, E. H., Ing, R. M. Y., Mueller, U. W., Powell, J., Griffin, P. D., and Stevens, V. C., 1988, Phase 1 clinical trial of a World Health Organization birth control vaccine, Lancet 1:1295–1298.PubMedCrossRefGoogle Scholar
  28. La Montagne, J. R., and Rabinovich, N. R., 1994, The promise of new technologies, Int. J. Tech. Assess. Health Care 10:7–13.CrossRefGoogle Scholar
  29. Lemon, S. M., and Milstien, J. B., 1994, The thermostability of vaccines: Technologies for improving the thermostability of the oral poliovirus vaccine, Int. J. Tech. Assess. Health Care 10:177–184.CrossRefGoogle Scholar
  30. Martinez-Palomo, A. M., Lopez-Cervantes, M., and Freeman, P., 1994, The role of vaccine research and development in the scientific development of middle-income countries, Int. J. Tech. Assess. Health Care 10:30–38.CrossRefGoogle Scholar
  31. Melnick, J. L., 1994, Live attenuated poliovirus vaccines, in: Vaccines, 2nd ed. (S A. Plotkin and E. A. Mortimer, Jr., eds.), Saunders, Philadelphia, pp. 155–204.Google Scholar
  32. Mestecky, J., Kutteh, W. H., and Jackson, S., 1994, Mucosal immunity in the female genital tract: Relevance to vaccinations efforts against the human immunodeficiency virus, AIDS Res. Hum. Retroviruses 10(Suppl. 1) (in press).Google Scholar
  33. Miller, C. J., Alexander, N. J., and McChesney, M. B., 1994, Vaccines to prevent sexually transmitted diseases: The challenge of generating protective immunity at genital mucosal surfaces, in: Strategies in Vaccine Design (G.L. Ada, ed.), R.G. Landes Company, Austin, TX, pp. 193–212.Google Scholar
  34. Mitchell, M. S., Harel, W., Kan-Mitchell, J., LeMay, L. G., Goedegebuure, P., Huang, X. Q., Hofman, F., and Groshen, S., 1993, Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action, Ann. N.Y. Acad. Sci. 690:153–166.PubMedCrossRefGoogle Scholar
  35. Mitchell, V. S., Philipose, N. M., and Sanford, J. P., (eds.), 1993, The Children’s Vaccine Initiative. Achieving the Vision, Institute of Medicine, National Academy Press, Washington, DC.Google Scholar
  36. National Academy of Science, Institute of Medicine, 1986, New vaccine development: Establishing priorities. Diseases of importance in the developing countries, National Academy Press, Washington, DC.Google Scholar
  37. National Institute of Allergy and Infectious Diseases, 1993, The Jordan Report. Accelerated Development of Vaccines — 1993, Bethesda, MD.Google Scholar
  38. Oaks, S. C., Mitchell, V. S., Pearson, G. W., and Carpenter, C. C. J., (eds.), 1991, Malaria: Obstacles and Opportunities, National Academy Press, Washington, DC.Google Scholar
  39. Ognibene, A. J., and Barrett, O., Jr., (eds.), 1982, Internal Medicine in Vietnam. Vol. II. General Medicine and Infectious Diseases, Office of the Surgeon General and Center of Military History, United States Army, Washington, DC.Google Scholar
  40. Parker, D., and Hill, T., 1994, The contribution of immunization to economic development, Int. J. Tech. Assess. Health Care 10:21–29.CrossRefGoogle Scholar
  41. Parkman, P. D., and Hardegree, M. C., 1994, Regulation and testing of vaccines, in: Vaccines, 2nd ed. (S. A. Plotkin and E. A. Mortimer, Jr., eds.), Saunders, Philadelphia, pp. 889–901.Google Scholar
  42. Patriarca, P. A., Wright, P. F., and John, T. J., 1991, Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: A review, Rev. Infect. Dis. 13:926–939.PubMedCrossRefGoogle Scholar
  43. Plotkin, S. L., and Plotkin, S. A., 1994, A short history of vaccination, in: Vaccines, 2nd ed. (S. A. Plotkin and E. A. Mortimer, Jr., eds.), Saunders, Philadelphia, pp. 1–11.Google Scholar
  44. Robbins, A., and Arita, I., 1994, The global capacity for manufacturing vaccines. Prospects for competition and collaboration among producers in the next decade, Int. J. Tech. Assess. Health Care 10:39–46.CrossRefGoogle Scholar
  45. Safranek, T. J., Lawrence, D. N., Kurland, L. T., Culver, D. H., Wiederholt, W. C., Hayner, N. S., Osterholm, M. T., O’Brien, P., Hughes, J. M, and the Expert Neurology Group, 1991, Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976–1977: Results of a two-state study, Am. J. Epidemiol. 133:940–951.PubMedGoogle Scholar
  46. Smith, S. J., Lawrence, D. N., and Noble, G. R., 1984, An immune response profile model for immunogenicity quantitation, J. Theor. Biol. 110:1–10.PubMedCrossRefGoogle Scholar
  47. Ward, J., Lieberman, J. M., and Cochi, S. L., 1994, Haemophilus influenzae vaccines in: Vaccines, 2nd ed. (S.A. Plotkin and E.A. Mortimer, Jr., eds.), Saunders, Philadelphia, pp. 337–386.Google Scholar
  48. Wassilak, S. G. F., Glasser, J. W., Chen, R. T., and Hadler, S. C., 1995, Utility of large-linked databases in vaccine safety, particularly in distinguishing independent and synergistic effects, in: Proceedings of the workshop on combined vaccines and simultaneous administration: Current issues and perspectives, Ann. N.Y. Acad. Sci. (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Dale N. Lawrence
    • 1
  • Karen L. Goldenthal
    • 2
  • John W. Boslego
    • 3
  • Donna K. F. Chandler
    • 2
  • John R. La Montagne
    • 4
  1. 1.Division of AIDS, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA
  2. 2.Division of Vaccines and Related Products Applications, Center for Biologics Evaluation and ResearchFood and Drug AdministrationRockvilleUSA
  3. 3.Walter Reed Army Institute of ResearchUSA
  4. 4.Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA

Personalised recommendations